Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease
C Burton, P Allen, AF Herrera - American Society of Clinical Oncology …, 2024 - ascopubs.org
Combination chemotherapy with or without radiation has served as the primary therapeutic
option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of …
option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of …
Emerging immunotherapies in the Hodgkin lymphoma armamentarium
MA Spinner, RH Advani - Expert Opinion on Emerging Drugs, 2024 - Taylor & Francis
Introduction Brentuximab vedotin and PD-1 inhibitors have improved outcomes for classic
Hodgkin lymphoma (cHL), but better therapies are needed for patients who relapse after …
Hodgkin lymphoma (cHL), but better therapies are needed for patients who relapse after …
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study
NS Grover, G Hucks, ML Riches, A Ivanova… - The Lancet …, 2024 - thelancet.com
Background Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have
promising activity when preceded by lymphodepleting chemotherapy. We aimed to …
promising activity when preceded by lymphodepleting chemotherapy. We aimed to …
Treatment approaches for older Hodgkin lymphoma patients
PJ Bröckelmann - Current Opinion in Oncology, 2024 - journals.lww.com
Current Opinion in Oncology Log in or Register Subscribe to journalSubscribe Get new issue
alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation Subscribe …
alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation Subscribe …
What is the best salvage therapy for Hodgkin lymphoma?
E Luttwak, AJ Moskowitz - Current Opinion in Oncology, 2024 - journals.lww.com
The landscape of HL treatment is rapidly evolving, leading to significant changes in the
standard of care. Novel agents are now administered earlier in the disease course, resulting …
standard of care. Novel agents are now administered earlier in the disease course, resulting …
[HTML][HTML] The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
AF Cashen - Frontiers in Oncology, 2024 - pmc.ncbi.nlm.nih.gov
Since their initial approval as single agent therapy for multiply relapsed/refractory Hodgkin
lymphoma (HL), the PD-1 inhibitors nivolumab and pembrolizumab have been incorporated …
lymphoma (HL), the PD-1 inhibitors nivolumab and pembrolizumab have been incorporated …
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management
SM Ansell - American journal of hematology, 2024 - Wiley Online Library
Abstract Disease Overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid
malignancy affecting 8570 new patients annually and representing~ 10% of all lymphomas …
malignancy affecting 8570 new patients annually and representing~ 10% of all lymphomas …
[引用][C] Hodgkin Lymphoma: Next Questions
AJ Moskowitz - Clinical Lymphoma Myeloma and Leukemia, 2024 - Elsevier